StoryResearch
Novo Nordisk reports Amycretin Phase 1b/2a results: 22% weight loss at 36 weeks with weekly injection
Novo Nordisk announced positive Phase 1b/2a results for amycretin, its next-generation GLP-1 and amylin receptor agonist dual agonist. In a 36-week trial of the injectable form, patients receiving the highest weekly dose (20 mg) achieved 22% weight loss. The company also reported 13.1% weight loss with the oral daily formulation over 12 weeks in Phase 1.
- Dose escalation study: 9.7% at 1.25 mg (20 weeks), 16.2% at 5 mg (28 weeks), 22.0% at 20 mg (36 weeks)
- Oral amycretin showed promise with 13.1% weight loss on daily dosing for 12 weeks; higher pill burden requires further optimization.
- Regulatory feedback supported advancing both subcutaneous and oral forms to Phase 3, starting Q1 2026.
- Safety profile consistent with incretin-based therapies; gastrointestinal events were most common and predominantly mild to moderate.